Product Description
Epitinib could cross BBB and show its efficacy in brain metastasis tumors. For Treating Patients With Glioblastoma (Sourced from: https://clinicaltrials.gov/ct2/show/NCT03231501)
Mechanisms of Action: EGFR Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: HUTCHMED
Company Location: HONG KONG K3 00000
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Non-Small-Cell Lung Cancer
Phase 1: Oncology Solid Tumor Unspecified|Glioblastoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 2016-813-00CH3 | P1 |
Unknown status |
Glioblastoma |
2020-06-30 |
41% |
| 2010-813-00CH1 | P1 |
Completed |
Oncology Solid Tumor Unspecified |
2019-04-30 |
|
| CTR20170170 | N/A |
Suspended |
Glioblastoma |
None |
|
| CTR20160660 | P3 |
Suspended |
Non-Small-Cell Lung Cancer |
None |